PDF(Pubmed)
Abstract：
Osteoarthritis (OA) is a chronic disorder caused by degenerative changes in articular cartilage, which are mainly manifests as degeneration of cartilage, subchondral bone remodeling, as well as synovial inflammation. Over the next few decades, OA and its burden will continue to increase worldwide, posing a major public health challenge for the foreseeable future. Treatment for OA includes non-pharmacological, pharmacological, and surgical treatments. Existing conservative treatments and joint surgery can only alleviate the symptoms and cannot be cured, so new therapies for OA are urgently needed. Since advances in the understanding of OA pathophysiology, researchers have identified some potential therapeutic targets against degeneration of cartilage, subchondral bone remodeling and synovial inflammation, enabling development of the disease-modifying OA drugs (DMOADs). Additionally, a number of new technologies are also being investigated for treating OA, such as RNA interference (RNAi), CRISPR/Cas9 and PROTAC. The goal of this review is to describe the current development status of DMOADs and to discuss the potential of emerging therapeutic approaches for treating OA, thus providing a reference for OA treatments.
摘要：
骨关节炎(OA)是一种由关节软骨退行性改变引起的慢性疾病,主要表现为软骨退化，软骨下骨重建，以及滑膜炎.在接下来的几十年里，OA及其负担将在全球范围内继续增加，对可预见的未来构成重大公共卫生挑战。OA的治疗包括非药物治疗，药理学,和手术治疗。现有的保守治疗和关节手术只能缓解症状，无法治愈，因此，迫切需要新的OA疗法。由于对OA病理生理学的理解有了进展，研究人员已经确定了一些针对软骨退化的潜在治疗靶点，软骨下骨重塑和滑膜炎症，能够开发改善疾病的OA药物（DMOAD）。此外,一些治疗OA的新技术也在研究中，如RNA干扰（RNAi），CRISPR/Cas9和PROTAC。这篇综述的目的是描述DMOAD的当前发展状况，并讨论治疗OA的新兴治疗方法的潜力，从而为OA治疗提供参考。
